Transplantation of genetically modified haematopoietic stem cells to induce antigen-specific tolerance as a cure for autoimmune diseases

Current Stem Cell Research and Therapy

Volumn 6, Issue 1, 2011, Pages 44-49

  Chan, James ^a   Alderuccio, Frank ^b   Toh, Ban Hock ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmune diseases; Dendritic cells; Haematopoietic stem cells; Immune tolerance; Tissue repair; Transplantation

Indexed keywords

ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3;

ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; ENVIRONMENTAL FACTOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; THYMUS; TISSUE REGENERATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; GENE THERAPY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSION; RECOMBINANT FUSION PROTEINS; REGENERATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 79551655118     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811794480672     Document Type: Article

References (64)

1. Rose NR, Mackay IR. In: The Autoimmune Diseases. Elsevier Academic Press. 2006.
2. Morton JI, Siegel BV. Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc Natl Acad Sci USA 1974; 71: 2162-5.
3. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 1994; 12: 125-35.
4. Mellouli F, Ksouri H, Torjmen L, et al. Transmission of type 1 diabetes by bone marrow transplantation: a case report. Pediatr Transplant 2009; 13: 119-22
5. van Bekkum DW. Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol 2002; 72: 609-20
6. Marmont AM. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 2008; 30: 145-50
7. Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435: 590-7
8. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004; 4: 688-98
9. Kubach J, Becker C, Schmitt E, et al. Dendritic cells: sentinels of immunity and tolerance. Int J Hematol 2005; 81: 197-203
10. Gotter J, Kyewski B. Regulating self-tolerance by deregulating gene expression. Curr Opin Immunol 2004; 16: 741-5
11. Liston A, Gray DH, Lesage S, et al. Gene dosage--limiting role of aire in thymic expression, clonal deletion, and organ-specific auto- immunity. J Exp Med 2004; 200: 1015-26
12. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 2001; 86: 337-45
13. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol (Suppl) 1997; 48: 23-9
14. Lu Q, Lu L, Niu X, Guo Y, Parino GR, Liu D. Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus. Bone Marrow Transplant 2006; 37: 979-81
15. Burt RK, Oyama Y, Verda L, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chi-merism. Arthritis Rheum 2004; 50: 2466-70
16. Khorshid O, Hosing C, Bibawi S, et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 2004; 31: 2513-6
17. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997; 19: 395-7
18. Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol 2000; 247: 691-5
19. Jeffery DR. Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis. Mult Scler 2007; 13: 1071-5
20. van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989; 86: 10090-4
21. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005; 141: 1-9
22. Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005; 128: 432-59
23. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004; 126: 637-49
24. Fassas A. Autologous stem cell transplants in treatment of multiple sclerosis: where we stand and future prospects. Int J Hematol 2002; 76 (Suppl) 1: 223-225
25. Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30
26. Saiz A, Blanco Y, Berenguer J, et al. Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurologia 2008; 405-7
27. Passweg J, Tyndall A. Autologous stem cell transplantation in autoimmune diseases. Semin Hematol 2007; 44: 278-85
28. Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol 2005; 4: 54-63
29. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-53
30. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 168-76
31. Hugle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther 2008; 10: 217
32. Hare KJ, Pongracz J, Jenkinson EJ, Anderson G. Modeling TCR signaling complex formation in positive selection. J Immunol 2003; 171: 2825-31
33. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997; 185: 541-50
34. Jenkinson EJ, Anderson G, Moore NC, Smith CA, Owen JJ. Positive selection by purified MHC class II+ thymic epithelial cells in vitro: costimulatory signals mediated by B7 are not involved. Dev Immunol 1994; 3: 265-71
35. Proietto AI, van Dommelen S, Wu L. The impact of circulating dendritic cells on the development and differentiation of thymo-cytes. Immunol Cell Biol 2009; 87: 39-45
36. Li J, Park J, Foss D, Goldschneider I. Thymus-homing peripheral dendritic cells constitute two of the three major subsets of dendritic cells in the steady-state thymus. J Exp Med 2009; 206: 607-22
37. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006; 7: 1092-100
38. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711
39. Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008; 29: 362-71
40. Yamazaki S, Steinman RM. Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J Dermatol Sci 2009; 54: 69-75
41. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2: 301-6
42. Aschenbrenner K, D'Cruz LM, Vollmann EH, et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007; 8: 351-8
43. Alderuccio F, Toh BH, Tan SS, Gleeson PA, van Driel IR. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J Exp Med 1993; 178: 419-26
44. French MB, Allison J, Cram DS, et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997; 46: 34-9
45. Xu H, Wawrousek EF, Redmond TM, et al. Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis. Eur J Immunol 2000; 30: 272-8
46. Murphy K, Biondo M, Toh BH, Alderuccio F. Tolerance established in autoimmune disease by mating or bone marrow transplantation that target autoantigen to thymus. Int Immunol 2003; 15: 269-77
47. Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest 2003; 111: 1357-63
48. Chan J, Ban EJ, Chun KH, et al. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol 2008; 181: 7571-80
49. Chan J, Clements W, Field J, et al. Transplantation of bone marrow genetically engineered to express proinsulin II protects against autoimmune insulitis in NOD mice. J Gene Med 2006; 8: 1281-90
50. Xu B, Haviernik P, Wolfraim LA, Bunting KD, Scott DW. Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther 2006; 13: 42-48
51. Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig KW, Iacomini J. Prevention of type 1 diabetes by gene therapy. J Clin Invest 2004; 114: 969-78
52. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40
53. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008; 14: 337-42
54. Tian C, Bagley J, Iacomini J. Persistence of antigen is required to maintain transplantation tolerance induced by genetic modification of bone marrow stem cells. Am J Transplant 2006; 6: 2202-7
55. Jeffries GH, Todd JE, Sleisenger MH. The effect of prednisolone on gastric mucosal histology, gastric secretion, and vitamin B 12 absorption in patients with pernicious anemia. J Clin Invest 1966; 45: 803-12
56. Wall AJ, Whittingham S, Mackay IR, Ungar B. Prednisolone and gastric atrophy. Clin Exp Immunol 1968; 3: 359-66
57. Zorina TD, Subbotin VM, Bertera S, et al. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 2003; 21: 377-88
58. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-72
59. Perier O, Gregoire A. Electron microscopic features of multiple sclerosis lesions. Brain 1965; 88: 937-52
60. Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 2005; 48: 9-12
61. Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology 2001; 142: 4956-68
62. Biondo M, Field J, Toh BH, Alderuccio F. Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis. J Pathol 2006; 209: 384-91
63. Chan J, Ban EJ, Chun KH, et al. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 2008; 41: 405-13
64. Lindner M, Heine S, Haastert K, et al. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol Appl Neu-robiol 2008; 34: 105-14